345 related articles for article (PubMed ID: 35874956)
21. Exploring peptide studies related to SARS-CoV to accelerate the development of novel therapeutic and prophylactic solutions against COVID-19.
Madhavan M; AlOmair LA; Ks D; Mustafa S
J Infect Public Health; 2021 Aug; 14(8):1106-1119. PubMed ID: 34280732
[TBL] [Abstract][Full Text] [Related]
22. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
[TBL] [Abstract][Full Text] [Related]
23. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
[TBL] [Abstract][Full Text] [Related]
24. [Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection].
Troldborg A; Bartels LE; Deleuran B
Ugeskr Laeger; 2020 May; 182(20):. PubMed ID: 32400380
[TBL] [Abstract][Full Text] [Related]
25. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
Meo SA; Klonoff DC; Akram J
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4539-4547. PubMed ID: 32373993
[TBL] [Abstract][Full Text] [Related]
27. Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery.
Chen Y; Li MX; Lu GD; Shen HM; Zhou J
Int J Biol Sci; 2021; 17(6):1538-1546. PubMed ID: 33907517
[TBL] [Abstract][Full Text] [Related]
28. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
29. Discovering small-molecule therapeutics against SARS-CoV-2.
Tiwari V; Beer JC; Sankaranarayanan NV; Swanson-Mungerson M; Desai UR
Drug Discov Today; 2020 Aug; 25(8):1535-1544. PubMed ID: 32574699
[TBL] [Abstract][Full Text] [Related]
30. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
[TBL] [Abstract][Full Text] [Related]
31. SARS-CoV-2 Infection Triggers Phosphorylation: Potential Target for Anti-COVID-19 Therapeutics.
Chatterjee B; Thakur SS
Front Immunol; 2022; 13():829474. PubMed ID: 35251015
[TBL] [Abstract][Full Text] [Related]
32. An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges.
Xu X; Chen Y; Lu X; Zhang W; Fang W; Yuan L; Wang X
Biochem Pharmacol; 2022 Nov; 205():115279. PubMed ID: 36209840
[TBL] [Abstract][Full Text] [Related]
33. Host sphingolipids: Perspective immune adjuvant for controlling SARS-CoV-2 infection for managing COVID-19 disease.
Prakash H; Upadhyay D; Bandapalli OR; Jain A; Kleuser B
Prostaglandins Other Lipid Mediat; 2021 Feb; 152():106504. PubMed ID: 33147503
[TBL] [Abstract][Full Text] [Related]
34. Chloroquine and its derivatives in the management of COVID-19: A scoping review.
Pimentel J; Andersson N
Biomedica; 2020 Oct; 40(Supl. 2):80-95. PubMed ID: 33152192
[TBL] [Abstract][Full Text] [Related]
35. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
[TBL] [Abstract][Full Text] [Related]
36. Targeting the sAC-Dependent cAMP Pool to Prevent SARS-Cov-2 Infection.
Aslam M; Ladilov Y
Cells; 2020 Aug; 9(9):. PubMed ID: 32854430
[TBL] [Abstract][Full Text] [Related]
37. Ototoxicity prevention during the SARS-CoV-2 (COVID-19) emergency.
Ciorba A; Skarżyński PH; Pelucchi S; Hatzopoulos S
J Glob Antimicrob Resist; 2020 Dec; 23():263-264. PubMed ID: 33075521
[TBL] [Abstract][Full Text] [Related]
38. Chloroquine and COVID-19-A systems biology model uncovers the drug's detrimental effect on autophagy and explains its failure.
Kapuy O; Korcsmáros T
PLoS One; 2022; 17(4):e0266337. PubMed ID: 35390060
[TBL] [Abstract][Full Text] [Related]
39. When RING finger family proteins meet SARS-CoV-2.
Cai C; Tang YD; Zheng C
J Med Virol; 2022 Jul; 94(7):2977-2985. PubMed ID: 35257387
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive Analysis of SARS-COV-2 Drug Targets and Pharmacological Aspects in Treating the COVID-19.
Bhavaniramya S; Ramar V; Vishnupriya S; Palaniappan R; Sibiya A; Vaseeharan B
Curr Mol Pharmacol; 2022; 15(2):393-417. PubMed ID: 34382513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
